Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Seeker who wrote (66554)	2/1/2001 9:58:25 AM
From: Sharck	Respond to of 122087

An old favorite of yours should move up today... Thursday February 1, 7:20 am Eastern Time ImClone wins U.S. fast track review for carcinoma drug NEW YORK, Feb 1 (Reuters) - Biotechnology company ImClone Systems Inc. (NasdaqNM:IMCL - news) on Thursday said its experimental treatment for colorectal tumors resistant to standard treatment has won fast track review designation from U.S. regulators. Fast track review means the U.S. Food and Drug Administration will expedite review of a drug if it is intended for the treatment of a serious or life-threatening condition, and it demonstrates the potential to address unmet medical needs. The company's drug, IMC-C225, is undergoing a series of mid- and late-stage tests on humans, the company said. The drug is a so-called anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody. ImClone is studying the effect of IMC-C225, in combination with standard cancer treatments, on refractory, or treatment resistant, colorectal carcinoma. Carcinoma is a new growth or malignant tumor that forms in tissue on the body's surface, inside body cavities, or passageways leading out of the body. The company is also conducting tests on refractory head and neck carcinoma and pancreatic carcinoma.